Gene Editing of Embryos Gives Insight Into Basic Human Biology
By Marissa Fessenden,
Smithsonian.com [cites CGS' Marcy Darnovsky]
| 09. 21. 2017
A genetic tool allows researchers to disable a gene key to human development in a closely regulated experiment
For the first time, scientists edited a gene in fertilized human eggs critical to early development. The experiments helped the researchers learn about fundamental human biology in a way they could not through research on mice.
Researchers led by Kathy Niakan, a developmental biologist at the Francis Crick Institute in London, disabled a gene that codes for a protein called OCT4, known to be active in stem cells that can develop into all the cell types found in the body, reports Gretchen Vogel for Science. Turning the gene off ensured that cells from fertilized human eggs failed to form placental cells, yolk sac cells or even cells that would typically become a fetus.
Disabling the same gene in mouse embryos gives different results: Those embryos became balls of mostly placental cells. The findings suggest that the gene controls the fate of several cell lineages and plays a slightly different role in humans than in mice.
"This is opening up the possibility...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...